Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 6
2007 10
2008 6
2009 5
2010 3
2011 3
2012 2
2014 2
2015 2
2016 7
2017 11
2018 4
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

57 results
Results by year
Filters applied: . Clear all
Page 1
TNF-alpha in promotion and progression of cancer.
Balkwill F. Balkwill F. Cancer Metastasis Rev. 2006 Sep;25(3):409-16. doi: 10.1007/s10555-006-9005-3. Cancer Metastasis Rev. 2006. PMID: 16951987 Review.
Cancer-related inflammation.
Mantovani A, Allavena P, Sica A, Balkwill F. Mantovani A, et al. Nature. 2008 Jul 24;454(7203):436-44. doi: 10.1038/nature07205. Nature. 2008. PMID: 18650914 Free article. Review.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
Tumour necrosis factor and cancer.
Balkwill F. Balkwill F. Nat Rev Cancer. 2009 May;9(5):361-71. doi: 10.1038/nrc2628. Epub 2009 Apr 3. Nat Rev Cancer. 2009. PMID: 19343034 Review.
Paraneoplastic thrombocytosis in ovarian cancer.
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Stone RL, et al. N Engl J Med. 2012 Feb 16;366(7):610-8. doi: 10.1056/NEJMoa1110352. N Engl J Med. 2012. PMID: 22335738 Free PMC article. Clinical Trial.
Inflammation and cancer: advances and new agents.
Crusz SM, Balkwill FR. Crusz SM, et al. Nat Rev Clin Oncol. 2015 Oct;12(10):584-96. doi: 10.1038/nrclinonc.2015.105. Epub 2015 Jun 30. Nat Rev Clin Oncol. 2015. PMID: 26122183 Review.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. Lin KK, et al. Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13. Cancer Discov. 2019. PMID: 30425037 Free article. Clinical Trial.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL. Kondrashova O, et al. Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z. Nat Commun. 2018. PMID: 30266954 Free PMC article.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Oza AM, et al. Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4. Gynecol Oncol. 2017. PMID: 28882436 Free article. Clinical Trial.
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden K, Lockley M, McNeish IA. Walton J, et al. Cancer Res. 2016 Oct 15;76(20):6118-6129. doi: 10.1158/0008-5472.CAN-16-1272. Epub 2016 Aug 16. Cancer Res. 2016. PMID: 27530326 Free PMC article.
57 results
Jump to page
Feedback